抗HIV新药--CCR5拮抗剂马拉韦罗
被引量：3
摘要
艾滋病病毒(HIV)突变耐药是艾滋病治疗中的一个突出问题,为此人们必须不断研制新型药物来抵抗出现的耐药株。2007年8月7日,抗HIV新药——CCR5拮抗剂马拉韦罗被美国食品药品管理局(FDA)批准上市。该文综述了马拉韦罗的作用机制、药动学、药效学、临床研究、不良反应以及与其他药物的相互关系等。
出处
《中国艾滋病性病》
CAS
2008年第4期431-434,共4页
Chinese Journal of Aids & STD
参考文献12
-
1O' Brien SJ, Moore JP.The effect of genetic vaiation in chemokines and their receptors on HIV transmission and progression to AIDS[J].Immunol Rev,2000,177:99 - 111.
-
2Dorr P,Westby M,Dobbs S,et al. Maraviroc(UK-427,857),a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity [ J ] .Antimicrob Agents Chemother, 2005,49( 11 ) : 4721 - 4732.
-
3VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. Criteria for Use : Maraviroc (Selzentry) Available at http://www.pbm. va. gov/criteria/Maraviroc.20 % Criteria 20% for 20% Use20% (Check-Box 20% Format).pdf Accessed on Nov 2,2007.
-
4Briggs DR, Tuttle DL, Sleasman JW, et al. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages) [J]. AIDS, 2000,14 (18) : 2937 - 2939.
-
5Skrabal K, Low AJ, Dong W, et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic mode [J].J Clin Microbiol,2007,45(2) :279 - 284.
-
6MeHale M,Abel S,Russell D,et al.Overview of phase 1 and 2a safety and efficacy data of maraviroc ( UK-427,857 )[A] . Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment [ C]. 2005, Rio de Janeiro, Brazil. Abstract Tuoa 0204.
-
7Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1[J] .Nat Med,2005,11(11) :1170- 1172.
-
8Pfizer Inc. Press Release: Maraviroc Reduces HIV Viral Load IN Treatment-Naive Patients, 48 Week Data Show (press release)[Z]. 2007.
-
9Lalezari J, Goodrich J, DeJesus E. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremia ART-experienced patients infected with CCR5-tropic HIV-1:24-week results of a Phase 2b/3 study in the US and Canada[ Z]. Postrer presented at the 14th Conference on Retroviruses and Opportunistic Infections;2007 February 25 - 28 ; Los Angeles, CA, USA.
-
10Nelson M, Fatkenheuer G, Konourina I. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremia ART-experienced patients infected with CCRS-tropic HIV-1 in Europe,Australia,and North America:24-week results[ Z]. Poster presented at the 14th Conference on Retroviruses and Opportunistic Infections;2007 February 25 - 28 ; Los Angeles, CA, USA.
同被引文献22
-
1Alkhatib G,Combadiere C,Broder C C,et al.CC CKR5:a RANTES,MIP-1 alpha,MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1[J].Science,1996,272:1955-1958.
-
2Deng H,Liu R,Ellmeier W,et al.Identification of a major co-receptor for primary isolates of HIV-1[J].Nature,1996,381:661-666.
-
3Kamp C.Understanding the HIV coreceptor switch from a dynamical perspective[J].BMC Evol Biol,2009,9:274.
-
4Wu Y,Yoder A.Chemokine coreceptor signaling in HIV-1 infection and pathogenesis[J].PLoS Pathog,2009,5:e1000520.
-
5Hu Q Y,Fink E,Hong Y,et al.Fine definition of the CXCR4-binding region on the V3 loop of feline immunodeficiency virus surface glycoprotein[J].PLoS One,2010,5:e10689.
-
6Reynes J,Portales P,Segondy M,et al.CD4+ T cell surface CCR5 density as determining factor of virus load in persons infected with human immunodeficiency virus type 1[J].J Inf Dis,2000,181:927-932.
-
7Lin Y L,Metting C,Portales P,et al.Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection[J].Proc Natl Acad Sci USA,2002,99:15590-15595.
-
8Schols D.HIV co-receptor inhibitors as novel class of anti-HIV drugs[J].Antiviral Res,2006,71:216-226.
-
9Zhao Q,He Y X,Alespeiti G,et al.A novel assay to identify entry inhibitors that block binding of H IV-1 gp120 to CCR5[J].Virology,2004,326:299-309.
-
10NOTARI S,TOMMASI C,NICASTRI E,et al.Simultaneousdetermination of maraviroc and raltegravir in human plasma byHPLC-UV[J].IUBMB Life,2009,61(4):470-475.
引证文献3
-
1石英,刘宁,计云霞,魏征,张彤,陈德喜,娄金丽.外周血CD4^+T淋巴细胞表面CCR5受体表达水平与HIV感染关系的研究[J].首都医科大学学报,2010,31(6):711-714. 被引量：1
-
2张霞.高效液相色谱法测定马拉韦罗片的含量[J].中国新药与临床杂志,2012,31(2):110-112.
-
3陈文文,刘新泳.马拉维罗合成路线图解[J].中国药物化学杂志,2012,22(2):170-172.
-
1张霞.高效液相色谱法测定马拉韦罗片的含量[J].中国新药与临床杂志,2012,31(2):110-112.
-
2新的CCR5拮抗剂有希望用于HIV感染成人的治疗[J].传染病网络动态,2005(12):15-15.
-
3一种新的CCR5拮抗剂有望用于HIV成人感染的治疗[J].中华医学信息导报,2005,20(22):8-8.
-
4何日才,郭长彬,周化,李振中.抗HIV新药利匹韦林的药理及临床评价[J].中国新药杂志,2012,21(9):947-951.
-
5张小林,徐红蓉,李雪宁.新类型的抗HIV药物——CCR5拮抗剂[J].中国临床药学杂志,2009,18(4):252-257. 被引量：3
-
6黄敏燕（摘）.09055 Maraviroc获得FDA的批准[J].国外药讯,2007(9):31-31.
-
7周斌.艾滋病治疗药物进展[J].医药导报,1993,12(2):89-92. 被引量：2
-
8王爱霞.艾滋病治疗的新进展[J].临床内科杂志,2000,17(4):197-198.
-
9封宇飞,傅得兴.CCR5阻滞剂马拉韦罗的药理与临床评价[J].中国新药杂志,2008,17(17):1544-1547. 被引量：1
-
10马培奇.新型抗艾滋病药马拉韦罗的临床地位及市场潜力[J].上海医药,2009,30(1):37-38.
